Carenostics vs Carna Health (2026)
Both attack undiagnosed chronic disease, with kidney disease at the centre of each, and they reach for different instruments. Carenostics reads what is already in the record, including the unstructured notes, to surface patients whose disease is present and unrecognised, with its own model behind it. Carna pairs point of care testing with a platform that ingests laboratory results, device data, record data and social determinants, so the at risk patient can be tested rather than referred into a gap. Carna's interoperability work is real and hard. Its AI claim is not inspectable at all: no architecture, validation method or accuracy figure was located anywhere, alongside no privacy statement or attestation. If you are buying detection intelligence, Carenostics is the one you can interrogate. If you are buying a testing and care pathway, Carna is selling that.
- It reads the record you already have, including unstructured notes, so no new test or device is required to surface an undiagnosed patient.
- The target is chronic disease that is present and unrecognised, which is a different problem from screening a population that has not been tested.
- Model ownership sits with the vendor, so accuracy questions have one accountable party.
- It pairs point of care testing with the platform, so a patient identified as at risk can be tested in the same visit rather than referred and lost.
- The interoperability work is the real and difficult part of the product, ingesting results from laboratories, devices, record systems and social determinants data.
- Its geographic reach is unusually broad for the segment, which matters for an organisation operating outside a single national health system.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Carenostics and Carna Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Carenostics | Carna Health |
|---|---|---|
| Primary category | Clinical Decision Support | Value Based Care Intelligence |
| Founded | Not recorded | 2021 |
| Headquarters | Not recorded | Boston, Massachusetts, United States |
| Website | carenostics.com | carna.health |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Carenostics its top capability grade on AI Centrality and Deployment Model and Data Residency. Set against Carna Health, Carenostics grades higher on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Its thinnest published disclosure sits on several axes, including HIPAA and BAA Posture, Security Certifications and Trust Center and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for Carna Health on any axis it scores. Set against Carenostics, Carna Health grades higher on Setting and Specialty Coverage. Its thinnest published disclosure sits on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Carenostics or Carna Health?
On the axes where the AI Health Index separates them, Carenostics grades higher on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure, and Carna Health grades higher on Setting and Specialty Coverage. Carenostics leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Carenostics and Carna Health differ most?
The widest separation the AI Health Index records between Carenostics and Carna Health is on AI Centrality, where Carenostics grades A and Carna Health grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Carenostics and Carna Health grade the same?
The AI Health Index grades Carenostics and Carna Health the same on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Carenostics and Carna Health not disclosed?
At the last review, at least one of Carenostics and Carna Health published thin or absent detail on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Carna describes itself as AI driven across nearly all its material while publishing nothing inspectable: no architecture, feature description, validation methodology or accuracy figure was located across repeated searches, and no health privacy statement, business associate terms or security attestation either. Read the AI claim accordingly. Carenostics publishes no retention or secondary use position.
Both products create downstream cost the vendor does not carry: identifying an at risk patient generates testing, follow up and sometimes treatment, and in a value based contract that near term cost precedes any saving by years.